RecruitingPhase 2NCT05985850

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy for Individuals Living With Opioid Use Disorder: A Phase II, Placebo-controlled, Blinded, Pilot Study to Assess Safety and Feasibility (THC-MMT)

Sponsor

BC Centre on Substance Use

Enrollment

24 participants

Start Date

May 23, 2024

Study Type

INTERVENTIONAL

Conditions

Opioid-use Disorder Cannabis Fentanyl Methadone

Summary

This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.

Eligibility

Min Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aurora 1:1 Drops (Indica) and a drug called Placebo for people with cannabis, fentanyl, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 25 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAurora 1:1 Drops (Indica)

Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.

DRUGPlacebo

Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).